



- Achieve Financial Goals** ● Revenue \$336M*; ● EBITDA \$84M* Up 6%; ● Cash Flow from Operations \$55M*
- Deliver Quality** ● Achieve product safety-related complaint rates below designated levels by product:
Exogen </1%; HA </0.05%; Bone Grafts </0.4%
- Operate with Integrity** ● Hold ourselves individually and collectively accountable for zero tolerance for willful deviation from company policies, and applicable laws and regulations
- Impact Patients** ● Improve Quality of Life for 385,000* patients using Bioventus Products
- Develop Ourselves** ● Promote career growth opportunities with a 50% Internal Promotion Rate
● Communicate Employee Engagement Survey results, engage teams to address top 3 findings, Q4

Become #1 US HA Market by 2022

- Capture \$19.2M in revenue from UHC commercial contract, Q4

Launch next generation treatments for Osteoarthritis

- Launch GTP Placental tissue product, per launch plan, Q4
- Submit Investigational New Drug (IND) application to FDA for “Biologic” Placental Tissue product, Q3

Expand with new products and markets

- Complete Project Sunrise, identify new growth opportunities, present options for Board approval, Q3

Expanded on-label indications for Exogen - BONES

- Submit PMA for metatarsal to FDA, Q4

Support continued growth of Surgical products

- Launch Signafuse Bioactive Strip, Q3

Complete Public Company Readiness Initiative

- Confirm All personnel and processes in place and operational, Q2

Strengthen Exogen “Prescription to Cash” Process

- Complete full process and system assessment and implement changes required, Q4